Achilles Therapeutics plc (NASDAQ:ACHL) Short Interest Update

Achilles Therapeutics plc (NASDAQ:ACHL) saw a large increase in short interest in the month of January. As of January 15th, there was short interest totalling 122,300 shares, an increase of 35.4% from the December 31st total of 90,300 shares. Based on an average daily volume of 169,400 shares, the days-to-cover ratio is presently 0.7 days. Currently, 0.3% of the company’s shares are short sold.

Achilles Therapeutics Price Performance

NASDAQ ACHL opened at $1.13 on Thursday. Achilles Therapeutics has a 1-year low of $0.63 and a 1-year high of $1.76. The firm has a market capitalization of $46.44 million, a P/E ratio of -0.68 and a beta of 1.32. The business’s 50-day simple moving average is $1.10 and its 200-day simple moving average is $0.96.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Achilles Therapeutics stock. BML Capital Management LLC grew its holdings in Achilles Therapeutics plc (NASDAQ:ACHL) by 555.8% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 4,100,002 shares of the company’s stock after acquiring an additional 3,474,828 shares during the period. Achilles Therapeutics comprises approximately 2.5% of BML Capital Management LLC’s holdings, making the stock its 11th biggest holding. BML Capital Management LLC owned about 9.98% of Achilles Therapeutics worth $4,182,000 as of its most recent SEC filing. 56.38% of the stock is owned by hedge funds and other institutional investors.

Achilles Therapeutics Company Profile

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient.